Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

The National Institutes of Health (NIH) is soliciting applications for the Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) to support biologic-based therapeutic discovery and development for the treatment of nervous system and neuromuscular disorders. This Funding Opportunity Announcement (FOA) will support preclinical discovery and development of potential therapeutic biotechnology products and biologics. Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacokinetics, toxicology, and Phase I clinical testing. • The BPN-Biologics program provides support for biologic-based therapeutic discovery and development. • Applicants will collaborate with NIH-funded consultants and can work with NIH contract research organizations. • The program aims to develop potential therapeutic biotechnology products and biologics for the treatment of nervous system and neuromuscular disorders. • The opportunity is open to various types of organizations, including public and state-controlled institutions of higher education, private institutions of higher education, and for-profit organizations. • The application due date is August 18, 2027.